Breast Ca Mortality Decline Greatest in Younger ER+ Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen-receptor (ER)-positive tumors and women younger than age 70

BETHESDA, Maryland—A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen-receptor (ER)-positive tumors and women younger than age 70 (J Clin Oncol published online April 2, 2007). Between 1990 and 2003, breast cancer mortality rates declined by 24%. The researchers found that among women under age 70, mortality declined 38% for those with ER-positive tumors vs 19% for ER-negative tumors, and among women 70 or older, by 14% for ER-positive tumors vs no decline for ER-negative tumors.

"These trends since 1990 are likely attributable to at least two factors: the use of tamoxifen after surgery . . . and widespread use of screening mammography, which is more likely to detect the slow-growing tumors that tend to be ER-positive," said lead author Ismail Jatoi, MD, PhD, of the Uniformed Services University of the Health Sciences.

Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content